HIK.L
Hikma Pharmaceuticals PLC
LSEGBpEQUITY
Healthcare
DELAYED
Last price
1,636.00
▲ 12.00 (0.74%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1,620.00
Prev close
1,624.00
Day high
1,636.00
Day low
1,607.80
Volume
511.57K
Market cap
$3.39B
P/E (TTM)
12.68
52W range
1,187.00 – 1,865.00
Day trading desk
Gap from prior close
-0.25%
Prior close 1,624.00
VWAP
1,622.67
+0.82% from price
Relative volume
0.55×
Quiet session
Session range
1.75%
1,607.80 – 1,636.00
Position in range
100%
Near session high
ATR (14D)
47.96
2.93% of price
Prior day high
1,664.00
PDH
Prior day low
1,612.00
PDL
Bid / ask spread
—
Quote not published
Session volume
584.25K
Avg 1.05M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.24%
+1.1%
1M
+5.34%
+1.6%
3M
+10.54%
+7.4%
6M
+0.18%
-10.9%
YTD
+5.55%
-6.7%
1Y
-10.89%
-30.9%
3Y
-22.90%
-97.1%
5Y
-35.34%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on HIK.L open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
71.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | Hikma Pharmaceuticals PLC |
BUY | 113.11K | $2.47M | Direct |
| Aug 13, 26 | Hikma Pharmaceuticals PLC |
BUY | 108.69K | $2.38M | Direct |
| Aug 12, 26 | Hikma Pharmaceuticals PLC |
BUY | 113.15K | $2.49M | Direct |
| Aug 12, 26 | Boston Partners International Equity Pooled Fund (Canada) |
— | 4.67M | — | Direct |
| Aug 11, 26 | Hikma Pharmaceuticals PLC |
BUY | 114.44K | $2.50M | Direct |
| Aug 10, 26 | Hikma Pharmaceuticals PLC |
BUY | 114.67K | $2.54M | Direct |
| Aug 10, 26 | Hestler (Tobias) |
BUY | 7.50K | $165.01K | Direct |
| Aug 7, 26 | Hikma Pharmaceuticals PLC |
BUY | 118.82K | $2.69M | Direct |
| Aug 7, 26 | Boston Partners International Equity Pooled Fund (Canada) |
— | 1.95M | — | Direct |
| Aug 6, 26 | Hikma Pharmaceuticals PLC |
BUY | 97.15K | $2.23M | Direct |
| Aug 5, 26 | Hikma Pharmaceuticals PLC |
BUY | 118.38K | $2.50M | Direct |
| Aug 4, 26 | Hikma Pharmaceuticals PLC |
BUY | 117.64K | $2.49M | Direct |
| Aug 3, 26 | Hikma Pharmaceuticals PLC |
BUY | 117.52K | $2.48M | Direct |
| Jul 31, 26 | Hikma Pharmaceuticals PLC |
BUY | 115.89K | $2.47M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Al-Husry (Ali) |
— | 1.16M | Annual Return |
BlackRock Inc. |
— | 10.00M | Annual Return |
Boston Partners International Equity Pooled Fund (Canada) |
— | 3.55M | Decrease |
Darhold Ltd |
— | 60.00M | Annual Return |
Darwazah (Said Samih Taleb) |
— | 1.54M | Bought |
Darwazeh (Mazen Samih Taleb) |
— | 2.17M | Bought |
Hikma Pharmaceuticals Employee Benefit Trust |
— | 1.46M | Annual Return |
Hikma Pharmaceuticals PLC |
— | 12.83M | Buy Back |
Kanaan (Bassam Wael Roshdi) |
— | 762.21K | Bought |
Vanguard Group Inc. |
— | 10.31M | Decrease |
Fundamentals
Market cap$3.39B
Enterprise value$5.23B
Revenue (TTM)$3.42B
Gross profit$1.51B
EBITDA$879.00M
Net income$387.00M
EPS (TTM)$1.29
Free cash flow$14.38M
Total cash$289.00M
Total debt$1.96B
Book value / share$8.54
Shares outstanding207.23M
Float146.44M
Short % of float—
Dividend yield3.88%
Beta (5Y)0.66
Valuation & profitability ratios
Trailing P/E12.68
Forward P/E8.95
PEG ratio1.71
Price / sales—
Price / book191.50
EV / revenue1.53
EV / EBITDA5.94
Gross margin44.05%
Operating margin23.49%
Profit margin11.32%
Return on equity15.41%
Return on assets7.47%
Debt / equity77.11
Current ratio1.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.35B | $3.13B | $2.88B | $2.52B | — | +7.1% |
| Operating revenue | $3.35B | $3.13B | $2.88B | $2.52B | — | +7.1% |
| Cost of revenue | $1.91B | $1.71B | $1.49B | $1.28B | — | +11.4% |
| Gross profit | $1.44B | $1.42B | $1.39B | $1.24B | — | +1.8% |
| Research & development | $151.00M | $141.00M | $149.00M | $144.00M | — | +7.1% |
| Selling, general & admin | $566.00M | $568.00M | $544.00M | $615.00M | — | -0.4% |
| Total operating expense | $808.00M | $803.00M | $780.00M | $756.00M | — | +0.6% |
| Operating income | $633.00M | $612.00M | $610.00M | $482.00M | — | +3.4% |
| Net interest income | -$91.00M | -$80.00M | -$80.00M | -$67.00M | — | -13.8% |
| Pre-tax income | $519.00M | $455.00M | $281.00M | $233.00M | — | +14.1% |
| Tax provision | $112.00M | $93.00M | $89.00M | $42.00M | — | +20.4% |
| Net income | $402.00M | $359.00M | $190.00M | $188.00M | — | +12.0% |
| Net income to common | $402.00M | $359.00M | $190.00M | $188.00M | — | +12.0% |
| Basic EPS | 1.82 | — | 0.86 | 0.84 | 1.82 | — |
| Diluted EPS | 1.81 | 1.61 | 0.85 | 0.84 | — | +12.4% |
| EBIT | $607.00M | $530.00M | $354.00M | $292.00M | — | +14.5% |
| EBITDA | $845.00M | $698.00M | $552.00M | $485.00M | — | +21.1% |
| Basic shares | 220.59M | 221.33M | 220.86M | 224.00M | — | -0.3% |
| Diluted shares | 222.68M | — | 222.37M | 225.00M | 233.00M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $217.00M | $188.00M | $205.00M | $270.00M | +15.4% |
| Cash & short-term investments | $243.00M | $213.00M | $229.00M | $292.00M | +14.1% |
| Accounts receivable | $997.00M | $896.00M | $789.00M | $777.00M | +11.3% |
| Inventory | $1.11B | $986.00M | $891.00M | $776.00M | +12.2% |
| Total current assets | $2.64B | $2.26B | $2.10B | $2.00B | +16.8% |
| Property, plant & equipment | $1.45B | $1.33B | $1.14B | $1.08B | +9.2% |
| Goodwill & intangibles | $1.17B | $1.16B | $1.10B | $1.12B | +1.2% |
| Total assets | $5.67B | $5.13B | $4.68B | $4.47B | +10.5% |
| Total current liabilities | $1.45B | $1.98B | $1.34B | $1.08B | -26.5% |
| Current debt | $106.00M | $642.00M | $150.00M | $139.00M | -83.5% |
| Long-term debt | $1.45B | $607.00M | $975.00M | $1.07B | +138.1% |
| Total debt | $1.60B | $1.31B | $1.19B | $1.28B | +22.8% |
| Total liabilities | $3.06B | $2.81B | $2.47B | $2.32B | +9.0% |
| Retained earnings | $2.56B | $2.36B | $2.16B | $2.09B | +8.2% |
| Shareholder equity | $2.59B | $2.31B | $2.20B | $2.13B | +12.3% |
| Working capital | $1.19B | $285.00M | $761.00M | $922.00M | +317.5% |
| Net tangible assets | $1.42B | $1.15B | $1.10B | $1.01B | +23.3% |
| Shares issued | 234.72M | 234.72M | 233.91M | 233.07M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $519.00M | $455.00M | $281.00M | $233.00M | — | +14.1% |
| Depreciation & amortisation | $238.00M | $168.00M | $198.00M | $193.00M | — | +41.7% |
| Stock-based compensation | $23.00M | $27.00M | $25.00M | $22.00M | — | -14.8% |
| Change in working capital | -$251.00M | -$135.00M | $80.00M | -$131.00M | — | -85.9% |
| Operating cash flow | $436.00M | $564.00M | $608.00M | $585.00M | — | -22.7% |
| Capital expenditure | -$317.00M | -$235.00M | -$204.00M | -$225.00M | — | -34.9% |
| Investing cash flow | -$388.00M | -$381.00M | -$333.00M | -$607.00M | — | -1.8% |
| Share buybacks | — | — | $0 | -$300.00M | $0 | — |
| Dividends paid | -$185.00M | -$175.00M | -$137.00M | -$125.00M | — | -5.7% |
| Financing cash flow | -$25.00M | -$188.00M | -$337.00M | -$58.00M | — | +86.7% |
| Free cash flow | $119.00M | $329.00M | $404.00M | $360.00M | — | -63.8% |
| End cash position | $217.00M | $188.00M | $205.00M | $270.00M | — | +15.4% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $217.00M | $236.00M | $188.00M | -8.1% |
| Cash & short-term investments | $243.00M | $236.00M | $213.00M | +3.0% |
| Accounts receivable | $997.00M | $1.07B | $896.00M | -6.7% |
| Inventory | $1.11B | — | $986.00M | — |
| Total current assets | $2.64B | — | $2.26B | — |
| Property, plant & equipment | $1.45B | $1.37B | $1.33B | +5.5% |
| Goodwill & intangibles | $1.17B | — | $1.16B | — |
| Total assets | $5.67B | $5.55B | $5.13B | +2.1% |
| Total current liabilities | $1.45B | $2.06B | $1.98B | -29.3% |
| Current debt | $106.00M | — | $642.00M | — |
| Long-term debt | $1.45B | $798.00M | $607.00M | +81.1% |
| Total debt | $1.60B | $1.56B | $1.31B | +3.0% |
| Total liabilities | $3.06B | $3.00B | $2.81B | +2.1% |
| Retained earnings | $2.56B | $2.47B | $2.36B | +3.4% |
| Shareholder equity | $2.59B | $2.54B | $2.31B | +2.2% |
| Working capital | $1.19B | $501.00M | $285.00M | +137.5% |
| Net tangible assets | $1.42B | — | $1.15B | — |
| Shares issued | 234.72M | — | 234.72M | — |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 2.28 | 10 | $3.46B | +3.4% |
| Next year | 2.49 | 10 | $3.61B | +4.2% |
Analyst targets & ownership
Mean target$1,875.55
High target$2,593.96
Low target$1,307.23
Implied upside14.64%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 8
Hold0
Sell / Strong sell0 / 1
Held by insiders32.91%
Held by institutions36.48%
Institutions holding218
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1,642.60
-0.40% from price
SMA 20
1,626.30
+0.60% from price
SMA 50
1,572.06
+4.07% from price
SMA 100
1,488.00
+9.95% from price
SMA 200
1,489.10
+9.86% from price
EMA 12
1,635.26
+0.04% from price
EMA 26
1,613.44
+1.40% from price
EMA 50
1,575.77
+3.82% from price
RSI (14)
54.8
Neutral
MACD (12,26,9)
21.82
Hist -3.33
ATR (14)
47.96
2.93% of price
Realised vol 30D
33.6%
Annualised
Bollinger upper
1,696.51
20, 2σ
Bollinger lower
1,556.09
20, 2σ
50 / 200 cross
Golden
1,572.06 vs 1,489.10
Trend bias
Above 200
+9.86%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.21
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
33.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.7%
Peak to trough
Max drawdown 5Y
-54.3%
Peak to trough
ATR 14
47.96
2.93% of price
Beta (reported)
0.66
5Y monthly, from filing
Dividends & splits
Forward rate$0.63 / yr
Forward yield3.88%
5-year avg yield2.90%
Payout ratio46.87%
Ex-dividend dateAug 13, 2026
Next pay date—
Last split—
Split date—
Headlines
147 Laps Around the Mall: Washington Hosts Freedom 250 Street Race
The Wall Street Journal · 5m ago
BC-Nikkei 225 Futures
Associated Press · 6m ago
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
Insider Monkey · 8m ago
The Committee for a Responsible Federal Budget Estimates Social Security Cuts for Couples if the System Is Not Fixed
Motley Fool · 16m ago
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Insider Monkey · 17m ago
Liverpool striker Isak expected Newcastle abuse, says Iraola
AFP · 17m ago
Your mortgage rate has a growing problem in the bond market
TheStreet · 19m ago
Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?
Insider Monkey · 23m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.